As payers tally up the potential costs of anti-amyloid antibodies for Alzheimer’s disease, a new study suggests that the vial design for Eisai and Biogen’s Leqembi could result in hundreds of millions ...

Medicare could waste up to $605 million per year on the controversial Alzheimer's drug aducanumab if it is eventually approved for widespread use because it is supplied in vials containing fixed doses ...

WASHINGTON, June 27 (UPI) --The vials containing an expensive, controversial drug for Alzheimer's disease are fixed in size, yet the amount required by patients varies widely, since it is administered ...

In Table 1, we describe six broad strategies that can be used to lower cancer drug dosing and reduce drug waste, many of which have already been clinically validated. Intravenous (IV) drug waste is ...